» Articles » PMID: 32152246

Non-Hodgkin Lymphomas: Malignancies Arising from Mature B Cells

Abstract

Non-Hodgkin lymphomas (NHLs) are a diverse group of entities, both clinically and molecularly. Here, we review the evolution of classification schemes in B-cell lymphoma, noting the now standard WHO classification system that is based on immune cell-of-origin and molecular phenotypes. We review how lymphomas arise throughout the B-cell development process as well as the molecular and clinical features of prominent B-cell lymphomas. We provide an overview of the major progress that has occurred over the past decade in terms of our molecular understanding of these diseases. We discuss treatment options available and focus on a number of the diverse research tools that have been employed to improve our understanding of these diseases. We discuss the problem of heterogeneity in lymphomas and anticipate that the near future will bring significant advances that provide a measurable impact on NHL outcomes.

Citing Articles

Using a Natural Triterpenoid to Unlock the Antitumor Effects of Autophagy in B-Cell Lymphoma.

Doonan B, Radwan F, Banik N, Haque A Biomedicines. 2025; 13(2).

PMID: 40002858 PMC: 11853664. DOI: 10.3390/biomedicines13020445.


Unveiling CKS2: A Key Player in Aggressive B-Cell Lymphoma Progression and a Target for Synergistic Therapy.

Zhou F, Chen L, Liu Z, Cao Y, Deng C, Liu G Cancer Med. 2024; 13(22):e70435.

PMID: 39560180 PMC: 11574738. DOI: 10.1002/cam4.70435.


Lymphoma dissemination is a pathological hallmark for malignant progression of B-cell lymphoma.

Li X, Jiang Y, Qian H Front Immunol. 2023; 14:1286411.

PMID: 38077394 PMC: 10703179. DOI: 10.3389/fimmu.2023.1286411.


Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies.

Martelli A, Paganelli F, Evangelisti C, Chiarini F, McCubrey J Cells. 2022; 11(11).

PMID: 35681507 PMC: 9180032. DOI: 10.3390/cells11111812.

References
1.
Meister A, Hentrich M, Wyen C, Hubel K . Malignant lymphoma in the HIV-positive patient. Eur J Haematol. 2018; 101(1):119-126. DOI: 10.1111/ejh.13082. View

2.
Clark H, Jones D, Wright D . Cytogenetic and molecular studies of t(14;18) and t(14;19) in nodal and extranodal B-cell lymphoma. J Pathol. 1992; 166(2):129-37. DOI: 10.1002/path.1711660208. View

3.
Italiano A, Soria J, Toulmonde M, Michot J, Lucchesi C, Varga A . Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018; 19(5):649-659. DOI: 10.1016/S1470-2045(18)30145-1. View

4.
Zhang J, Grubor V, Love C, Banerjee A, Richards K, Mieczkowski P . Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2013; 110(4):1398-403. PMC: 3557051. DOI: 10.1073/pnas.1205299110. View

5.
Fais F, Ghiotto F, Hashimoto S, Sellars B, Valetto A, Allen S . Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998; 102(8):1515-25. PMC: 509001. DOI: 10.1172/JCI3009. View